Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: Ronald Allen who wrote (467)	1/23/1998 8:06:00 PM
From: flickerful	Read Replies (2) \| Respond to of 756

IVAX Announces Generic Drug Approval For Prochlorperazine MIAMI, Jan. 23 /PRNewswire/ -- IVAX Corporation (Amex: IVX - news) today announced that the United States Food and Drug Administration approved its Abbreviated New Drug Application for the generic pharmaceutical product prochlorperazine maleate in 5 mg and 10 mg tablets. Prochlorperazine is indicated for control of severe nausea and vomiting and for management of the manifestations of psychotic disorders, and is the generic equivalent of SmithKline Beecham Pharmaceuticals' Compazine(R). The product will be marketed by IVAX's wholly-owned subsidiary, Zenith Goldline Pharmaceuticals, Inc., and shipping has commenced. IVAX Corporation, headquartered in Miami, Florida, is a holding company with core subsidiaries engaged primarily in the research, development, manufacture and marketing of generic and branded pharmaceuticals. SOURCE: IVAX Corporation ------------------------------------------------------------------------ More Quotes and News:Ivax Corp (AMEX:IVX - news)Related News Categories: biotech, medical/pharmaceutical ------------------------------------------------------------------------ Help